10x Genomics, Inc. (TXG) News
Track canonical SquawkNews coverage tagged to TXG, 10x Genomics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 16 indexed stories across 13 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Surgery Partners, 10x Genomics, QuidelOrtho, Zimmer Biomet, and Tandem Diabetes Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid Services moved to cancel Affordable Care Act coverage for roughl
REGULATION | Sep 23, 2026, 08:42 PM UTC
H
Radiant Logistics, Waystar, Forgent Power Solutions And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Dow Jones index falling around 300 points on Tuesday. Shares of Radiant Logistics Inc (NYSE: RLGT ) rose sharply after the company reported better-than-expected fourth-quarter financial r
LIVE | Sep 15, 2026, 01:53 PM UTC
L
Cathie Wood Makes Striking Switch Between AI Stock Giants
Cathie Wood's Ark Invest made a sharp rotation across technology and biotechnology stocks last week, buying roughly $28 million of Meta Platforms NASDAQ:META while selling a nearly identical dollar amount of Alphabet NAS
EQUITY | Sep 15, 2026, 12:21 PM UTC
L
UBS maintains neutral rating on 10x Genomics
UBS maintained a neutral rating on 10x Genomics, according to Benzinga ratings actions.
EQUITY | Sep 09, 2026, 06:08 PM UTC
L
10x Genomics director sells Class A stock for $1,235,071
Director John R Stuelpnagel reported Class A common stock sales on 2026-09-03, totaling $1,235,071 for 20,000 shares at weighted average prices of $60.6579, $62.1082 and $62.6066.
EQUITY | Sep 08, 2026, 11:10 PM UTC
L
RBC Capital sets $70 price target for 10x Genomics
Benzinga reports RBC Capital initiated coverage on 10x Genomics at Sector Perform and set a $70.00/share price target.
EQUITY | Sep 01, 2026, 12:11 PM UTC
L
IMR appoints independent director and names CFO
IMR appoints Paul Larkin as an independent director and Robert Scott as CFO.
EQUITY | Aug 31, 2026, 04:06 AM UTC
L
Qiagen owes 10x, Roche $4.8 million for infringing patents, U.S. jury says
Qiagen owes 10x, Roche $4.8 million for infringing patents, U.S. jury says
EQUITY | Aug 28, 2026, 09:23 PM UTC
M
10x Genomics jury finds Qiagen unit Parse Biosciences infringed
U.S. jury found a Qiagen unit infringed patents held by Parse Biosciences, per TradingView News.
EQUITY | Aug 28, 2026, 06:40 PM UTC
M
10x Genomics wins patent verdict against Parse Biosciences
10x Genomics won a patent infringement verdict against Parse Biosciences.
EQUITY | Aug 28, 2026, 06:39 PM UTC
L
Insiders sold TXG shares worth over $3.1M
Insiders at TXG sold shares worth over $3.1M, per TradingView News.
EQUITY | Aug 26, 2026, 08:52 PM UTC
L
10x Genomics Raises FY2026 Sales Guidance from $600.000M-$625.000M to $610.000M-$630.000M vs $613.851M Est
10x Genomics (NASDAQ: TXG ) raises FY2026 sales outlook from $600.000 million-$625.000 million to $610.000 million-$630.000 million vs $613.851 million estimate.
EARNINGS | Aug 06, 2026, 08:07 PM UTC
M
TXG Collaborates with Lausanne University Hospital
TXG partners with hospital for cancer research
EQUITY | Jul 29, 2026, 01:00 PM UTC
H
10x Genomics price target raised to $37 from $22 at Morgan Stanley
Morgan Stanley analyst Kallum Titchmarsh raised the firm's price target on 10x Genomics to $37 from $22 and keeps an Equal Weight rating on the shares. The firm is updating its model ahead of the earnings report.
EQUITY | Jul 09, 2026, 10:56 AM UTC
L
Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $42
Piper Sandler analyst David Westenberg maintains 10x Genomics (NASDAQ: TXG ) with a Neutral and raises the price target from $20 to $42.
EQUITY | Jul 01, 2026, 01:25 PM UTC
M
TXG: Barclays Raises Target
10x Genomics shares are trading higher after Barclays raised its price target on the stock from $30 to $40.
EQUITY | Jun 24, 2026, 07:47 PM UTC